about
Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemiaThe BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitorsA novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1Identification of cis-acting elements and splicing factors involved in the regulation of BIM Pre-mRNA splicingThe HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistanceThe role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia.Chemotherapy in malignant pleural mesothelioma. A review.A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides.Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice.Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer.Reply: the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia.The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional targetViable Mice with Extensive Gene Humanization (25-kbp) Created Using Embryonic Stem Cell/Blastocyst and CRISPR/Zygote Injection ApproachesAberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemiaBIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patientsLaying the foundation for genomically-based risk assessment in chronic myeloid leukemia
P50
Q28541556-0DC6FDDB-6D1B-48F7-956A-E477367DD124Q33418324-8B3BB83C-37DE-4AB0-957D-28D8A267EB80Q34589167-1E140513-8853-486B-9ED6-15940FC9AC6EQ35151577-C2731684-57C1-4FB3-99C6-F5C318BA4273Q36310881-175FA853-9E22-4F26-BE90-29B7A0311B58Q36771927-93E9ED08-FDC2-4323-8331-9AD180C724D9Q36959906-BDA01E39-6CFF-4A8C-A2DE-0823A205C9CCQ37984835-20CFBEF2-2ED8-47FD-8ACF-5D13F716973BQ38563914-6E83859B-319F-4017-BCF4-580137654A56Q38806879-EDD1E1E1-7BB6-4B82-B96F-382D6E02539BQ42424512-4C616C94-CC01-4908-B0B6-65D466A6540FQ45903443-6A46468F-14D8-4301-9839-4A21A4EE42BDQ47992960-3BEA56CC-FB9B-4E2C-8100-3D85858ACC6BQ48320164-98A95FF5-B650-400E-8920-B35C83DC5502Q51254509-E99941FA-3EDD-49E9-8E42-D6B05186F6B2Q55070789-4A911152-E44E-4F64-BD8C-BE07040EA67DQ57281862-6B79A561-8898-417D-96F6-48ABBF9112B8Q57292443-91C76602-50B3-4F9A-9710-5720F3F0437CQ77931481-50F35600-3CDF-43FE-8939-E58C67344681Q89147054-920C7EED-A891-4F57-9469-6D5D30831BC0Q92826117-2207BBD0-B20E-4A63-AABA-5DB266452F1A
P50
description
researcher
@en
wetenschapper
@nl
name
S T Ong
@en
S T Ong
@nl
type
label
S T Ong
@en
S T Ong
@nl
prefLabel
S T Ong
@en
S T Ong
@nl
P106
P31
P496
0000-0001-9460-3483